Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus IMULDOSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus IMULDOSA.
IMPOYZ vs IMULDOSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Imuldosa is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing terminal complement complex formation and complement-mediated cell lysis.
100 mg orally twice daily
1000 mg intravenously over 90 minutes every 4 weeks.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 27-33 hours in adults with normal renal function; prolongs to >50 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal excretion as unchanged drug (60-70%) and metabolites (15-20%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Unknown
Unknown